Aclaris prices $50 million stock offering after positive ATI-052 Phase 1b readouts

Aclaris Therapeutics priced a public offering on October 27, 2026 of 7,785,714 shares of common stock and pre-funded warrants for up to 6,500,000 additional shares, at $3.50 per share and $3.49999 per warrant. The company is offering 7,785,714 shares of common stock, plus pre-funded warrants for certain investors who prefer them, with each warrant priced at the common stock offering price minus $0.00001 and an exercise price of $0.00001 per share.¹ Aclaris estimated net proceeds of approximately $46.7 million after underwriting discounts and expenses.¹ Delivery of the securities is expected on or about October 28, 2026.¹

The financing follows the same-day release of primary analysis results from two Phase 1b proof-of-concept trials of ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, in atopic dermatitis and asthma. In the 14-patient AD trial, patients treated with ATI-052 saw a 45% placebo-adjusted mean improvement in EASI score from baseline at day 57, moving 58% in the ATI-052 arm versus 13% with placebo.¹ On itch, ATI-052 patients recorded a 43% placebo-adjusted mean improvement in PP-NRS at day 57, an absolute 38% gain versus a 5% worsening on placebo.¹

In the 16-patient asthma trial, a single 480 mg dose of ATI-052 produced a 59% mean reduction in FeNO at day 15, a 45 parts-per-billion absolute drop, versus 15% for placebo.¹ FEV1 improved by 200 mL at day 15 overall, and by 350 mL in a post hoc subgroup with baseline FEV1 under 80% predicted and reversibility, compared with a 140 mL decline on placebo.¹

Across both trials, ATI-052 was well tolerated, with mostly Grade 1 adverse events, no Grade 3 or 4 events, no discontinuations, and no conjunctivitis.¹ Aclaris intends to prioritize ATI-052 development first in eosinophilic esophagitis, starting a Phase 2b trial in early 2027, with an update on another indication expected in the near term.¹ As of September 30, 2026, the company estimated cash, cash equivalents and marketable securities of approximately $204.6 million.¹